Navigation Links
BioMS Medical to present at Sachs Associates Biotech in Europe Forum
Date:9/19/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Sept. 19 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Tony Hesby, Executive Vice President, Corporate Affairs, will present at the Sachs Associates 8th Annual Biotech in Europe Investor Forum in Zurich, Switzerland.

WHEN: Tuesday September 23rd at 11:25am (Local Time)

WHERE: Zurich, Switzerland

About Sachs Associates Biotech in Europe Investor Forum

-------------------------------------------------------

The forum is recognized as the leading international stage for those interested in investing in the biotech and life science industry and is highly transactional, drawing together an exciting cross-section of early-stage/pre-IPO, late-stage and listed companies with leading investors, analysts, money managers and pharmas.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...ria, November 6 EUCODIS Bioscience..., and marketing enzymes for the,chemical industry ...h,agreement with Bio Sidus, the leading biopharmac...greement gives EUCODIS Bioscience exclusive access...Sidus, proprietary collection of,psychrophilic bac...
(Date:11/6/2009)... The agenda for Arrowhead’s 2010 Personal...t to take place on February 22-24, 2010 in Philade...rence we will highlight key issues in forming part...ir experiences. , Minneap...r Arrowhead’s 2010 Personalized Medicine Pa...
(Date:11/5/2009)...5 Imagenetix, Inc. (OTC ...m Spencer, President and CEO of Imagenetix, will b... LD MICRO Conference on Thursday, December 3rd, at..., About LD MICRO ,, LD MICRO is a by-invitat...ndervalued companies in the micro-cap space. Since...
(Date:11/5/2009)...., Nov. 5 Cepheid (Nasda...l be speaking at the following investor conference...t. , , Credit Suisse Healthcare Co...2 November, 2009 at 10 a.m. Mountain Time, ..., England, Tuesday, 1 December, 20...
Breaking Biology Technology:EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2Cepheid to Webcast Upcoming Financial Presentations 2
...ted States Patent and Trademark Office has grante...e patent attorneys to re-examine three patents on ...Alumni Research Foundation (WARF). , ,The challe...Consumer Rights (FTCR) and the Public Patent Fou...ts that the groups say are impeding scientific pro...
...lete? Are you paying too much for too little? Unde...ng is very important in the selection process of t...enants who are contemplating a move to another bui...ay, some should be avoided because they offer noth...l competitiveness. Executives faced with reviewing...
...nc. , a supplier of high-density microarray produc...s through newly obtained intellectual property rig...firm , ,The license agreement will allow NimbleGen... microarrays and related instruments and software,...is used to study the relationships between genes a...
Other Biology Technology:WARF stem cell patents to be re-examined 2Making sure YourSpace is technologically sound 2Making sure YourSpace is technologically sound 3Making sure YourSpace is technologically sound 4Making sure YourSpace is technologically sound 5NimbleGen extends research market reach 2
(Date:11/4/2009)...ists at the University of North Carolina at Chapel...ifornia, San Francisco have developed and experime...seases for existing drugs. , The researchers dev...milar the structures of all known drugs are to the...ligands -- of disease targets within the cell. In ...
(Date:11/4/2009)...swire/ -- Glencoe Software, Inc., the commercial a...tium ( http://openmicroscopy.org ), is proud to ...ty of Cell Biology,s exciting new project titled "...rded a $2.5M stimulus grant through the National I...ogram, as part of the American Reinvestment and Re...
(Date:11/3/2009)...ber 4, 2009) For more than 25 years, all attempts...us gigas ) have been unsuccessfuluntil now. For th...ques to produce beaded (nucleated) and non-beaded ...eloped by scientists from Florida Atlantic Univers.... With less than two years of research and experim...
Breaking Biology News(10 mins):Study points to new uses, unexpected side effects of already existing drugs 2Glencoe Software to Support the ASCB 'Stimulus Grant' to Build Virtual Image Library of the Cell 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 3PROLOR Biotech Announces 2410 Million Preferred Stock Line From Members of The Frost Group 13188 1PROLOR Biotech Announces 2410 Million Preferred Stock Line From Members of The Frost Group 13188 2PROLOR Biotech Announces 2410 Million Preferred Stock Line From Members of The Frost Group 13188 3PROLOR Biotech Announces 2410 Million Preferred Stock Line From Members of The Frost Group 13188 4Growing Awareness and Increased Investments Lead to Growth of Biotechnology Applications in the Food 26 Beverage and Dietary Supplements Sector Reve 13186 1Growing Awareness and Increased Investments Lead to Growth of Biotechnology Applications in the Food 26 Beverage and Dietary Supplements Sector Reve 13186 2Growing Awareness and Increased Investments Lead to Growth of Biotechnology Applications in the Food 26 Beverage and Dietary Supplements Sector Reve 13186 3Growing Awareness and Increased Investments Lead to Growth of Biotechnology Applications in the Food 26 Beverage and Dietary Supplements Sector Reve 13186 4Spectrum Announces Fetal Bovine Serum Product Line 13184 1Spectrum Announces Fetal Bovine Serum Product Line 13184 2
...ncer stem cells, help brain tumors to buffer thems..."repair switch" that enables them to continue to g...cal Center have found. , The researchers also iden...bility to activate the repair switch following rad...elopment of therapies for overcoming radiation res...
...derale de Lausanne) have unveiled a new twist in a...lves against toxins made by disease-causing bacter... the September 22 issue of the journal Cell, advan...l response when attacked by bacteria and parasites...ess of cell membrane biogenesis. , Bacteria and ...
... biochip that measures the electrical activities o...data in just one reading than is possible with cur...could speed scientific research, which could accel...ers like epilepsy and help create more productive ...ment per day, as is often the case, this technolog...
Other Biology News:Cancer stem cells linked to radiation resistance 2Cancer stem cells linked to radiation resistance 3A new understanding of how cells defend themselves against bacterial pore-forming toxins 2A new understanding of how cells defend themselves against bacterial pore-forming toxins 3New biochip helps study living cells, may speed drug development 2New biochip helps study living cells, may speed drug development 3
...vice, We deliversoluble protein or No Charge to y...rotein results , 24 solubility optimization parame...sults on your most insoluble clones ,The new pro...oprietary tools and know-how recently developed at...
...roteomic scale kinase profiling, quantitative meas...covery research built on the flexible and powerful...These microarrays are available as part of our com...oarray Service. Custom Probe Content Probe cont...
...mmunological studies, vaccine development, and bio...ful Paraflo microfluidic on-chip synthesis platfor...comprehensive Epitope Peptide Microarray Service. ...y customer specified. Screen your samples against ...
... Edition of Molecular Imaging (MI) Software for us...arch and drug discovery applications. The Regulato...ood and Drug Administrations Code of Federal Regul...ronic Signatures [21 CFR Part 11]. KODAK MI Softwa...
Biology Products: